Nasodren®: How much time to symptom relief and clinical recovery?
Nasodren® has demonstrated its efficacy and safety in rhinosinusitis treatment in 15 comparative studies and in 7 cohort follow-up studies. In all of these studies, Nasodren® was administered at a dose of 2.6 mg /day (1.3 mg per nostril/ day) between 7 and 14 days in monotherapy or in combination.
In 5 of these studies (3 performed in adults and 2 in children) the time to symptom relief and clinical recovery with Nasodren® was compared with a combination of standard therapy.
Symptom relief: Nasodren® relieves symptoms after 3-4 days of treatment. In comparison with the conventional combination treatment, alone or in combination it shows a quicker recovery (3-4 versus 6-7 days) (1,2,3). Nasodren® administered in monotherapy shows similar efficacy than the standard combination treatment, but with a quicker recovery. In patients with purulent RS, Nasodren® also showed a quicker recovery, with a 4-day difference vs. conventional treatment group (7.3 versus 11.4 days) (1).
Clinical recovery (Cure): Nasodren® recovery from RS symptoms in 7-10 days of treatment, starting on days 6-7. Nasodren presents a faster cure
than the standard combined therapy (7-10 versus 10- 12 days) (1, 3). In children, Nasodrenâ recovery from clinical symptoms after 2-3 days of treatment. Nasodrenâ also normalized the rhinoscopic pattern quicker than in the control group (4-5 versus 8-10 days) (4,5).
In a cohort study, Nasodren® improved the overall state and reduced the relevant symptom in patients with ARS and CRS exacerbation in 5 days (6).
From this review it can be concluded that in all clinical studies Nasodren® shows that it is one of the treatment options for the beginning of an ARS episode, as monotherapy, even in non-purulent cases, as well as in combination. Compared with other treatments, Nasodren halved the time to relieve symptoms in adults and children, with a fast improvement in the general well-being and QoL of patients. Nasodren also reduces time to cure by 55% to 75% in comparison to the standard treatments, with an important contribution to the reduction of disease progression time, as well as to the number of complications and chronification (4).
BIBLIOGRAPHY
1) Mashkova TA, Matveeva VN. Objective evaluation of the effectiveness of secretolytic, secretostimulant therapy in complex treatment of acute rhinosinusitis. Russian Otorhinolaryngology 2007;5(30):109-112.
2) Ianov IuK, Riazantsev SV, Timchuk LE. [Efficacy of Sinuforte monotheraphy in patients with acute and chronic rhinosinusitis at an exacerbation stage]. Vestn Otorinolaringol 2007;(4):49-51.
3) Bogatov PP. Treatment of acute purulent sinusitis with Sinuforte. Rhinology, Journal of the Society of scientists and otorhinolaryngologists of Ukraine 2003:1.
4) Printz OM, Bashek V. Study of the use of Sinuforte® in the treatment of children with inflammatory conditions of the paranasal sinuses. Central Children’s Hospital in the city of ZHITOMIR (Ukraine). 2004.
5) Chernisheva LI, Siniachenko VV. Clinical and immunological investigation of the efficacy of Sinuforte use in children with acute sinusitis. J Otorynolaryngol Dis (Kiev) Special Edition 2004;3.
6) Timoshenko NA, Guriev TA. Experience on Sinuforte administration for the treatment of acute and chronic rhinosinusitis. 2nd International Conference of the Belarusian-Polish Otorhinolaryngologists. Grodno (Belarus), 2003.
7) Petrova LG. Treatment of exudative otitis media with Sinuforte. Journal of otorhinolaryngological diseases 2004;2.
